Treatment with Vyvgart (efgartigimod alfa-fcab) helped reduce the impact of generalized myasthenia gravis (gMG) on activities of daily living among adults who tested negative for antibodies targeting the acetylcholine receptor (AChR) […] The post Vyvgart eases gMG impact on daily living in seronegative adults in trial appeared first on Myasthenia Gravis News.
